NCT01008683UnknownNot Applicable
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
Hadassah Medical Organization1 site in 1 country300 target enrollmentStarted: November 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 300
- Locations
- 1
Study Overview
Brief Summary
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.
In these patients the investigators will measure the specific antibody production.
Detailed Description
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. Two doses will be given, in 3-week interval.
In these patients we will measure the specific antibody production. Blood sample 5 ml will be drawn before the first vaccine, before the second, and 3-4 weeks after the 2nd dose.
Study Design
- Study Type
- Observational
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- — to 80 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.
Exclusion Criteria
- •Patients with unstable grafts.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant PatientsOrgan TransplantationNCT01254955Sahlgrenska University Hospital, Sweden
Unknown
Not Applicable
Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as ReferenceHealthyNCT01039623Hadassah Medical Organization200
Unknown
Phase 2
Vaccination Against Influenza H1N1 in Rheumatic DiseasesRheumatic DiseasesInfluenzaNCT01006681Tel-Aviv Sourasky Medical Center400
Unknown
Not Applicable
Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and BiologicsInfluenza H1N1NCT01019837Tel-Aviv Sourasky Medical Center200
Unknown
Phase 3
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 MonthSwine-origin A/H1N1 InfluenzaInfluenzaNCT01040078Centers for Disease Control and Prevention, China900